asa recommendations glp-1 statement A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia The 2023 ASA position on
Description
Cayman offers these agents for research use only to support research in metabolic diseases like T2D and obesity
Theyve become some of the most widely discussed
This study compared the cardiovascular protective effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) versus sodium-glucose cotransporter-2 (SGLT2) inhibitors in this population

Pharmacology & Therapeutics, 155, 49-59

Roughly one in eight Americans say they are taking a GLP-1 drug -- and not just for weight loss
